Data on the Guardant Reveal™ minimal residual disease test in locally advanced rectal cancer patients enrolled in the NO-CUT trial will be presented in a proffered paper session during Presidential Symposium III.
For information and updates from the conference, follow Guardant Health on LinkedIn, X (Twitter) and Facebook (NASDAQ: ) or visit Guardant on-site at booth #510.
About Guardant HealthGuardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer.
These forward-looking statements should not be relied upon as representing Guardant Health's views as of any date subsequent to the date of this press release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240912788752/en/Investor Contact:Zarak Khurshidinvestors@guardanthealth.comMedia Contact:Mike Weistpress@guardanthealth.com+1 317 371 0035Source: Guardant Health, Inc.

Guardant Health to Share Data at ESMO 2024 Further Demonstrating Strong Performance of Its Precision Oncology Technology in Multiple Advanced Tumor Types By Investing.com